Lifestyle change reduces cardiometabolic risk factors and glucagon-like peptide-1 levels in obese first-degree relatives of people with diabetes.
Preventing type 2 diabetes in a real-world setting remains challenging. The present study aimed to assess the effectiveness of a lifestyle-based programme for individuals at high risk of developing type 2 diabetes as assessed by achieved weight loss, cardiovascular risk factors and glucagon-like peptide-1 (GLP-1).



Sixty-six obese individuals with history of diabetes in first-degree relatives participated in an 8-month lifestyle programme consisting of 12 × 1.25 h group education sessions led by dietitian and a weekly exercise programme. Before and after comparisons were made of fasting blood glucose, insulin, HbA1c, lipids, GLP-1 and quality of life (QoL).



Fifty-four participants of whom the majority were women [47 females; mean (SD) body mass index 35.3 (2.8) kg m-2; age = 52 (10) years] completed the 8-month programme. Mean (SD) weight loss was 10.1 (6.0) kg (P < 0.001). Out of 54 participants, 36 lost more than 7% of their body weight and 47 lost more than 5%, with significant improvements in cardiovascular risk factors, glycaemia and QoL scores. The fall was observed in basal (P < 0.05 versus baseline) but not stimulated GLP-1 levels. In the subgroup of participants losing >10 kg, a correlation was found between weight change and change in both basal (r = 0.61, P < 0.05) and stimulated (r = 0.49, P < 0.05) GLP-1.



An evidence-based lifestyle programme achieved sustained weight loss in obese first-degree relatives of individuals with type 2 diabetes associated with improvements in cardiometabolic risk factors and QoL without the 'voltage drop' of less benefit commonly seen when moving from the clinical trial experience into the real world.
Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.|Intermediate Dietetics Department, Dorset Healthcare University NHS Foundation Trust, Diabetes Centre, Poole, UK.
A
0000-0002-0652-4054
A
Bowes
Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.
J
J
Begley
Research and Innovation, William Sansum Diabetes Center, Santa Barbara, CA, USA.
D
D
Kerr
D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D008019:Life Style; D008875:Middle Aged; D065228:Non-Randomized Controlled Trials as Topic; D009765:Obesity / Q000097:blood* / Q000628:therapy; D011788:Quality of Life; D012307:Risk Factors; D015431:Weight Loss; D055815:Young Adult
D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007328:Insulin
diabetes prevention; lifestyle intervention; obesity; type 2 diabetes